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The  first  component  of  human  complement  (C1) 1  is  comprised  of three 
glycoprotein subunits, Clq, Clr, and Cls, held together in a calcium-dependent 
complex  (1-3).  The  interaction  of the  Clq  subunit  with  immune  complexes 
triggers  a  series of intramolecular  changes  in the C1 molecule leading to the 
conversion of C lr and C ls from inactive precursor molecules to active proteases, 
thus  initiating  the  classical complement pathway,  and  with it the  numerous 
biological  manifestations  of  complement  (4-8).  Although  physicochemical 
changes in the individual subunits have been documented (9-12), the correlates 
of these events in macromolecular C1 have not been thoroughly analyzed. 
We have recently reported that macromolecular C1 as well as free Cls can be 
directly demonstrated  and quantitated  in human serum by single and double 
immunodiffusion techniques. 2 In the course of these studies it became apparent 
that  activated  C1  gave  a  very different precipitation  pattern  than  native  C1 
with antisera  to Clq,  Clr,  and Cls in double immunodiffusion  analyses. The 
progressive  changes  in  the  C10uchterlony  pattern,  which  are  due  to  C1 
dissociation and also alterations  in antigenicity of the subunits,  are described 
here. Furthermore,  it is possible to measure some of these alterations by single 
radial diffusion techniques and thus directly quantitate C1 activation in human 
sera. 
Materials  and  Methods 
Materials and Proteins.  Methods for the purification and characterization of C lq, Clr, and C Is 
from human serum and for the production of monospecific antisera to each have been published 
(12-14).  Fresh human  serum  was  obtained  from  healthy  donors.  Bovine serum  albumin was 
purchased  from  Calbiochem  (San  Diego,  Calif.).  IgG  was  isolated  from  the  pseudoglobulin 
fraction  of human  serum  (5  mM  ethylene-diaminetetra-acetic  acid  (EDTA),  pH  5.4)  by  ion 
exchange chromatography on diethylaminoethyl cellulose in phosphate-buffered saline at pH 7.3. 
* Publication no. 1381 from Scripps Clinic and Research Foundation.  Supported by U. S. 
Public Health Service grant CA 14692, a program project  grant AI 07007, and Grant-in-Aid  77- 
941 from the American Heart Association. 
I  Abbreviations used in this  paper: agg IgG,  heat aggregated IgG; C1, first  component of 
human complement; CHso, dilution  of serum giving 50% lysis  of  sensitized  erythrocytes in the 
test  system; EDTA, ethylene-diaminetetra-acetic acid;  NHS, normal human serum. 
2  R. J. Ziccardi, and N. R. Cooper.  1978. Direct  demonstration and quantitation of  the first 
complement component in human serum. Science (Wash. D. C.  ). In press. 
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FIG. 1.  Effect  of  temperature on the immunodiffusion pattern of C1 in human serum. 
Normal human serum was allowed  to  diffuse  in  agarose containing calcium for  48  h at  4°C 
(left  panel)  or  22°C (right  panel).  The  single  fused  precipitin  line  observed  at  4°C  represents 
intact CI as Clq, Clr, and Cls antigens  are on the same molecule. A  very different 
pattern was obtained at  22°C. 
The IgG obtained was essentially  pure judged by polyacrylamide  gel electrophoresis  in sodium 
dodecyl sulfate.  Aggregation of  IgG was achieved  by incubation of  a 10  mg/ml sample at  63°C for 
20 rain after  which  particulate aggregates  were removed  by centrifugation in a  Beckman 
Microfuge (Beckman Instruments, Inc.,  Spinco Div.,  Palo Alto,  Calif.). 
Agarose was purchased from Marine Colloids,  Inc.,  Springfield,  N. J., sodium barbital  from 
Sigma Chemical Co.,  St. Louis, Mo., particulate  inulin  from Pfanstiehl  Labs.,  Inc.,  Waukegan, 
Ill.,  and zymosan from Nutritional Biochemicals  Corp.,  Cleveland, Ohio. Lipopolysaccharides 
from the heptose-deficient  rough mutant Salmonella Minnesota R-595 was kindly provided by 
Dr. D. Morrisen, Scripps Clinic  and Research Foundation, La  Jolla,  Calif. 
Hemolytic Assays.  Titrations  of  the complement activity  of  serum (CHso) and the hemolytic 
activity  of  C4 in  human serum were carried  out by published procedures (15,  16). 
Immunochemical Analyses.  Immunodiffusion analyses were performed in agarose in barbital- 
buffered  saline,  pH  7.2,  0.6  ×  physiological  ionic  strength  containing  2.5  mM  calcium  as 
described  earlier.  2  All  immunodiffusion studies  were  carried  out  for  48  h  at  4°C  or  room 
temperature as specified. 1 and 0.8% agarose was used for single radial and double immunodiffu- 
sion, respectively. The concentrations of anti-Clq,  anti-Clr, and anti-Cls or mixtures thereof 
used in the single radial diffusion analyses were determined as described earlier.  2 
Immunoelectrophoresis was  performed in  agarose in barbital-buffered saline pH  8.6,  0.6  × 
physiological ionic strength, containing 2.5 mM calcium. Electrophoresis was carried out for 4 h 
at 20 mA per slide at 4°C. 
Results 
Activation  of C1  in  Serum  during Immunodiffusion  Studies  at 22°C.  As 
we  have  reported  earlier,  antisera  to  Clq,  Clr,  and  Cls  gave  a  reaction  of 
identity  when  reacted  at  4°C  with  normal  human  sera  in  double  diffusion 
analyses in agarose containing calcium. 2 Grossly different Ouchterlony patterns 
were  obtained,  however,  when  identical  studies  were  carried  out  at  room 
temperature  (Fig.  1).  Under  these  conditions  multiple  crossing  lines  were ROBERT  J.  ZICCARDI  AND  NEIL  R.  COOPER 
TABLE  I 
Serum Complement Activation  by Aggregated IgG 
Amount Agg IgG 
added to NHS 
Percent complement consumption 
C4  CH~ 
mg/ml 
None  0  0 
0.2  32  43 
0.5  100  100 
1.0  100  100 
2.0  100  100 
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obtained  with  anti-Clq,  anti-Clr,  and  anti-Cls.  It  seemed  likely  that  the 
observed changes  in  the  double  diffusion  patterns  reflected  activation  of C1 
secondary  to  interaction  with  agarose  during  the  diffusion  process  at  22°C. 
Consistent with this interpretation,  serum incubated for 5 h  at room tempera- 
ture with 50 mg/ml of agarose lost 55% of its CHso, 36% of its C4, and 40% of its 
C2  activity,  while  serum  not  treated  with  agarose  lost  only  6,  4,  and  9%, 
respectively, on incubation at room temperature.  All values were compared to 
serum samples kept at 0°C for the same periods of time. 
Double Immunodiffusion  Analyses  of Activated  C1  in Human  Serum.  In 
these experiments,  fresh human  serum  was treated  for 60  min  at 37°C  with 
aggregated  IgG to activate serum  C1.  A  10-fold range  of activator  input was 
examined.  As shown in Table I,  complement activation,  as indicated by CHso 
depletion,  and  C1  activation,  as evidenced by C4 consumption,  were evident 
after incubation  of serum  with  0.2  mg/ml  of aggregated  IgG.  These  samples 
were subjected to double immunodiffusion analyses at 4°C as depicted in Fig. 2. 
Whereas the control serum gave the typical fused precipitin  line characteristic 
of C1 with anti-Clq,  anti-Clr  and anti-Cls,  a  markedly different pattern was 
observed on  analyzing  the  sera containing  activated  C1  (Fig.  2).  Changes  in 
the precipitin  lines representing  C1 as well as those due to Clq,  Clr,  and Cls 
reacting  with  their  respective  antibodies  were observed.  The  continuous  C1 
precipitin  line produced by anti-Clq,  anti-Clr,  and anti-Cls reacting with C1 
in serum disappeared as the dose of aggregated IgG increased.  In the case of 
Clq, spurring of the line produced by anti-Clq over that generated by anti-Clr 
was evident by the second dose of aggregated IgG, 0.5 mg/ml, and the intensity 
of the spur increased further with the dose of aggregates.  Simultaneously, the 
intensity  of the  precipitin  reaction  of Clr  with  its  antiserum  progressively 
decreased with increasing amounts of aggregated Ig and no clear Clr precipitin 
line  was  apparent  by 2  mg/ml  of aggregated  IgG.  Spurring  of the  anti-Cls 
precipitin  line  over the  lines  produced by anti-Clq  and  anti-Clr  was evident 
with the  lowest dose of aggregated  IgG.  The  intensity  of this  spur  increased 
with  the  addition  of progressively  larger  amounts  of aggregated  IgG to  the 
serum.  Results very similar to these were obtained with another C1 activator, 
bacterial lipopolysaccharide R-595. Spurring of the Cls line was observed when 
serum was treated with 0.2 mg/ml R-595 and disappearance of the Clr line was 
evident with 2 mg/ml R-595. On the other hand,  nonaggregated IgG (2 mg/ml), 
inulin  (20 mg/ml), and zymosan (5 mg/ml) produced minimal if any changes in 
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FIo. 2.  Effect  of  activation  on  the  immunodiffusion  pattern  of  C1 in  human serum. NHS 
was incubated for  i  h at  37°C alone  or  with  various  concentrations  of  heat  aggregated  IgG. 
The mixtures were subjected to double  immunodiffusion analyses  at 4°C in agarose 
containing calcium. Activation  of  C1 in serum was accompanied by a progressive  change 
in  the imrnunodiffusion pattern. 
Dissociation  of C1  in  Human  Serum  with  Activation.  The  most  likely 
interpretation  of the changing Ouchterlony pattern detailed above was that C1 
was undergoing progressive dissociation with increasing doses of C1 activator. 
While single radial diffusion studies of untreated normal human serum (NHS) 
in agarose containing equivalent concentrations of antibodies to Clq,  Clr,  and 
Cls  together  yielded  a  single  precipitin  ring, 2 multiple  rings  (two  to  three) 
were observed in identical studies of serum treated with complement activators, 
strongly supporting the concept that C1 was undergoing dissociation. 
Release of Cls from C1 in serum with activation was directly demonstrated 
by immunoelectrophoretic analyses of serum containing activated C1 in agarose 
in the presence of calcium (Fig. 3). Untreated normal serum or serum incubated 
with nonaggregated IgG showed a precipitin line with anti-Cls around the well 
of application,  as is characteristic of native C1 in serum. AfLer incubation with 
aggregated IgG, however, free Cls was detected in the serum (Fig.  3). 
Quantitation  of Cls  Released  with  C1  Activation.  Cls  released  during 
activation  of C1  in  serum  was quantitated  by single  radial  immunodiffusion 
analyses in agarose containing  calcium.  To differentiate free Cls from Cls in 
macromolecular C1, high concentrations of antibody to Clq were incorporated ROBERT  J.  ZICCARDI  AND  NEIL  R.  COOPER  389 
FIo.  3.  Demonstration of release of Cls with activation of C1 in human serum.  Human 
serum  was  incubated  for  1  h  at  37°C  with  2  mg/ml  of nonaggregated  IgG  (NHS)  or 
aggregated IgG (NHS), and then subjected to immunoelectrophoretic separation in agarose 
containing calcium.  Simultaneously,  Cls and Cls,  each at a  concentration of 30  ~g/ml, 
were analyzed. The pattern was developed with anti-Cls. Release of Cls with activation is 
evident. 
into the agarose to confine the Cls in the C1 complex to a precipitin ring at the 
application well, while low concentrations of antibody to Cls were employed to 
quantitate free Cls. 13, 24, 32, and 39 ~g/ml of free Cls were detected in serum 
incubated with 0.2,  0.5,  1.0,  and 2.0 mg/ml aggregated IgG, respectively (Fig. 
4).  The highest activator concentration released all of the Cls from the C1 in 
this serum. No free Cls was detected in untreated serum or serum treated with 
the same doses of nonaggregated IgG. 
Progressive Loss of Clr Antigenicity with C1 Activation.  The double immu- 
nodiffusion studies described above demonstrate a  diminution in intensity of 
the Clr precipitin line with the addition of increasing doses of aggregated IgG 
to serum  (Fig.  2).  Consistent with this finding, quantitative radial diffusion 
studies in the presence of EDTA showed a progressive reduction in serum Clr 
antigen  content  as  greater  amounts  of activator  were  added  to  the  serum 
(Table II).  It should be noted that no change in Clr content was observed on 
addition to serum of the same concentrations of nonaggregated IgG. Thus the 
Clr content decreased from 79% of the untreated serum value with an activator 
dose of 0.2  mg/ml to  19%  with  a  dose of 2.0  mg/ml.  On the other hand,  no 
change in total Cls content in the sera treated with the same doses of activator 
was observed (Table II). With the exception of the highest activator dose, Clq 
content also did not change. Therefore, C1 activation in serum can be detected 390  DEMONSTRATION  AND  QUANTITATION OF  C1  ACTIVATION 
FIG. 4.  Quantitation of Cls released with activation of C1  in human serum.  NHS was 
incubated for 1 h at 37°C alone or with various concentrations of heat aggregated IgG. The 
mixtures  were  subjected  to  single  radial  immunodiffusion analyses  at  4°C  in  agarose 
containing calcium and a high concentration of antibody to Clq to confine the intact C1 to 
a precipitin ring immediately surrounding the well of application. Low concentrations of 
anti-Cls were also incorporated into the agarose to permit quantitation of released Cls. 
The progressive release of Cls with increasing activator dose is evident (center column). 
The immunodiffusion plates also contained various amounts of isolated Cls (not shown)  to 
serve as standards for quantitation of released Cls (right column).  No free Cls was detected 
in untreated serum or serum treated with the same doses of nonaggregated IgG. 
as a  decrease in the Clr:Cls  ratio from the value of 1.0 characteristic of normal 
serum  (Table II). 
Discussion 
Macromolecular C1 can be detected in normal human  serum  as a  continuous 
line  of  precipitation  induced  by  anti-Clq,  anti-Clr,  and  anti-Cls  in  double 
immunodiffusion studies performed at 4°C,  as we have previously noted. 2 Very ROBERT  J.  ZICCARDI  AND  NEIL  R.  COOPER 
TABLE H 
Quantitation  of Clq, Clr, and Cls in Human Serum Treated with Various 
Doses of Aggregated IgG 
391 
Amount  agg  IgG 
added  to  NHS* 
Percent of  untreated  serum  concen-  Ratio  tration$ 
Clq  Clr  Cls  Clq/Cls  Clr/Cls 
rng/ml 
None  100  85  85  1.18  1.00 
0.2  100  79  82  1.22  0:96 
0.5  90  38  80  1.13  0.48 
1.0  89  25  79  1.13  0.32 
2.0  64  19  80  0.80  0.24 
*  All  samples  were  incubated  at  37°C  for  1  h. 
Determined  by  single  radial  immunodiffusion  in  agarose  containing  EDTA (17). 
different  Ouchterlony patterns were observed when the diffusion  studies were 
performed at room temperature (Fig.l).  The double diffusion  patterns at room 
temperature were found to be characteristic of activated C1 in serum  and 
identical  patterns were obtained at 4°C with serum previously incubated with 
complement activators such as aggregated IgG or R-595 lipopolysaccharide. In 
this  regard agarose was noted to effectively  activate C1 in serum at 22°C. 
It is apparent that the patterns  obtained with serum containing C1 are 
similar to those obtained with serum containing C1 dissociated  by addition of 
EDTA 2 although there are differences.  Dissociation of Clq and Cls from C1 
with activation is shown by the spurs of  the precipitin  lines  produced by these 
components reacting with their  respective antisera over that of  C1 (Figs. 1 and 
2). Release of  Cls, as shown by the spur,  is  evident at the lowest activator  dose 
examined (0.2  mg/ml) while dissociation  of Clq is only apparent with higher 
activator doses, suggesting that Cls is released at an earlier stage in the 
activation process than Clq. Interestingly, the Clq precipitin line does not 
penetrate or cross  the precipitin  line  due to released Cls, presumably because 
the released Clq bound to the Cls-anti-Cls  immune complex. Release of  Cls 
from the C1 complex with activation  was also demonstrated by immunoelectro- 
phoretic studies (Fig.  3). Additionally, single  radial  immunodiffusion analyses 
of  serum containing activated C1 yielded multiple rings in agarose containing 
antisera to Clq, Clr, and Cls. Although dissociation  of  CI with activation has 
not  previously been directly  demonstrated, Laurell  et  al.  found C ir  and C ls  with 
various electrophoretic  mobilities in the sera of  patients with certain diseases 
(18),  which is consistent with dissociation.  Bartholomew and Esser postulated 
dissociation  with activation as they were unable to find C1 in sucrose density 
gradient analyses of activated serum. 3 
Perhaps  the  most  surprising  change  in  the  Ouchterlony pattern  of serum 
containing  activated  C1  is  the  progressive  decrease  in  intensity  of the  Clr 
precipitin  line with the addition of increasing amounts of aggregated IgG (or 
R-595) to serum (Fig. 2).  In fact, no clear cut Clr precipitin line was evident on 
s  R. M. Bartholomew,  and  A. F.  Esser.  1977.  Exchange  of  radiolabeled  Cls  into  serum C1 and 
its  application  in  a  simplified  activation  assay.  J.  Immunol. In  press. 392  DEMONSTRATION  AND  QUANTITATION  OF  C1  ACTIVATION 
addition  of aggregated  IgG  to  a  concentration  of 2  mg/ml.  There  are  four 
possible explanations for the loss in Clr antigenicity with activation.  First, Clr 
after  activation  may become bound to  the  activating  substance  and  thus  be 
unable to diffuse into the agarose. This hypothesis requires that activated Clr 
bind firmly to each of the activators examined, i.e., aggregated IgG, LPS-R-595 
and  agarose,  as  loss  of Clr  antigenicity  was  observed with  each.  A  second 
possibility is that activated Clr,  like Clq and activated Cls, is released during 
C1 activation but then spontaneously aggregates, thus escaping detection with 
anti-Cir.  Isolated  Clr  converted into  Clr  by incubation  at  37°C  does in  fact 
aggregate  (R. J. Ziccardi and N. R. Cooper, unpublished observations). Third, 
the antigenicity of Clr may be lost because of structural rearrangements follow- 
ing the peptide bond cleavage which occurs with Clr activation  (9).  However, 
Clr and C~ formed by incubation of Clr at 37°C (9) give a reaction of identity 
using the same anti-Clr in double immunodiffusion analyses in agarose contain- 
ing EDTA with no trace of spurring and there is also no evidence of a reduction 
in intensity of the precipitin  line of C~ reacting with the antiserum  (unpub- 
lished observation). Nevertheless, it is possible that further changes occur in the 
Clr molecule with activation of C1 in serum leading to the production of a form 
of Cl'r different from that which was generated in vitro. A fourth possibility is 
that Clr antigenicity becomes completely masked by Clq,  Cls, or both in Ci. 
This is not likely, as Clr antigenicity in Ci is also not apparent on performing 
the studies in EDTA (Table II) which dissociates C1. A related possibility is that 
Cl-r  binds  to  Ci  inactivator  which  completely  masks  its  antigenicity.  This 
interaction  is known to be calcium independent.  In this regard,  Laurell et al. 
(18) felt Clr was present in a C~-Ci inactivator complex in certain pathological 
sera  although  they were unable  to  show precipitation  with  antisera  to  Clr. 
Experiments  are underway to differentiate between these hypotheses. 
Although the explanation  for the loss in C]~ antigenicity with activation is 
not yet clear,  this  observation,  along  with  the  finding  that  Cls  antigenicity 
does not change with activation, furnishes a practical approach to quantitating 
C1  activation  in  serum.  The  Clr:Cls  molar ratio  in  normal  human  serum is 
known to be unity (3). A decrease in the Clr:Cls molar ratio, as determined by 
quantitative  single  radial  diffusion  studies,  reflects  the  extent  of activation 
(Table II). 
An alternative  approach to quantitating  C1 activation in serum is based on 
the finding that Cls is released during the activation process (Fig. 3). Released 
Cls can be quantitated  in  the presence of macromolecular  C1 by performing 
radial  diffusion  analyses  in  agarose  containing  high  concentrations  of anti- 
Clq, to confine C1 to the area around the application well, and lesser concentra- 
tions of anti-Cls to permit free Cls to produce a  measurable ring of precipita- 
tion.  The quantity of Cls released from C1 was found to be proportional to the 
dose of activator added to the serum (Fig.  4). 
In another paper, techniques were presented which permit the quantitation 
of C1  and  free  C1  subunits  in normal  human  sera, 2 while the  present  study 
describes  two  alternative  approaches  to  the  detection  and  quantitation  of 
activation  of C1  in  normal  human  serum.  Presently,  intact  C1  can  be only 
measured  by  hemolytic  techniques  which  involve  specialized  reagents  and 
multiple  steps  (19)  and  activated  C1  can  be  measured  by  more  complex ROBERT  J.  ZICCARDI  AND  NEIL  R.  COOPER  393 
hemolytic  techniques  (20)  or  by indirect  approaches  based  on  its  ability  to 
inactivate C2 and C4 (21). There is no practical published method to quantitate 
free  C1  subunits  in  the  presence  of  macromolecular  C1.  The  techniques 
presented  here  and  in  the  other papeff will  thus  be useful in  analyzing  the 
properties and levels of macromolecular C1 and certain aspects of the activation 
process. 
The present approaches to quantitating  C1, free C1 subunits:and  C1 activa- 
tion in human sera have a  potentially wider range of usefulness as they may 
be of value in following the status of the complement system in the serum of 
patients  with  certain  diseases.  Reduced levels of C1  are  found  in  serum  of 
patients with several diseases (22) and there is also evidence for the presence of 
free  C1  subunits  in  some  pathologic  sera  (18).  de  Bracco  and  Manni  found 
several patients with decreased Clr:Cls ratios although a large pool of normals 
and  pathological  sera considered together  in  their  studies yielded a  constant 
Clr:Cls ratio (23). Circulating activated C1 is probably present in the serum of 
patients with complement consumptive process such as systemic lupus erythe- 
matosus as such sera frequently show strikingly  reduced levels of C2 and C4 
(22).  The approaches presented here should permit a  differentiation of disease 
related changes in synthesis of C1 subcomponents from consumptive processes. 
A reduction in the concentrations of Clq, Clr, and Cls with maintenance of an 
equimolar  ratio  would  suggest  a  coordinate  reduction  in  synthesis  of the 
subcomponents while a  selective reduction of the Clr level with no change in 
the Clq:Cls molar ratio would indicate activation. 
It remains to be determined whether the techniques presented here will be of 
sufficient sensitivity to be of value in achieving the above aims with patients' 
sera.  While these approaches  appear to be relatively insensitive  in  detecting 
activation  of C1  in  serum  induced  by aggregated  IgG,  results  obtained  with 
this  activator  obviously  cannot  be  extrapolated  directly  to  pathologic  sera 
containing  immune  complexes or other complement activators.  Hopefully the 
techniques will prove to be of aid in monitoring  the status of the complement 
system in patients. 
Summary 
Activation of the first component of human complement (C1) in human sera 
can be readily detected in double immunodiffusion studies with anti-Clq,  anti° 
Clr,  and anti-Cls  as it produces a  characteristic  pattern  quite different from 
that  of precursor  C1.  Native  macromolecular  C1  gives  a  continuous  line  of 
precipitation  with  antisera  to  Clq,  Clr,  and  Cls in  double diffusion studies. 
After  activation  of C1  by incubation  of serum  with  complement  activators, 
three  major changes  occurred  in  the  Ouchterlony  pattern.  First,  spurring  of 
the  Cls precipitin  line  over that  of macromolecular  C1,  indicating  release  of 
Cls  from  CI,  was  observed with  low doses of activator.  Release  of Cls  was 
quantitated  by  single  radial  diffusion  and  shown  to  be  complete  with  the 
highest activator dose examined. Second, C lq was released with larger activator 
doses as shown also by spurring  of the precipitin  line  due to this  component 
over  the  remaining  macromolecular  C1.  Third,  and  most  surprising,  Clr 
antigenicity was progressively lost as the activator dose was increased and no 
Clr line remained with the highest dose of activator tested. This was not true 394  DEMONSTRATION  AND  QUANTITATION OF  C1  ACTIVATION 
with  Cls  as  there  was  no  change  in  the  total  Cls  concentration  in  serum 
incubated with various activator doses. 
These observations provide two approaches to the quantitation  of C1 activa- 
tion in human  serum.  First,  Clr and  Cls can be quantitated  by single radial 
diffusion.  A  decrease  in  the  Clr:Cls  ratio  correlates  with  activation.  Second, 
Cls released by the activation can be quantitated  by single radial  diffusion if 
the  agarose  contains  high  concentrations  of  anti-Clq  to  confine  C1,  also 
containing Cls, to the area near the application well, and lesser concentrations 
of anti-Cls  to  permit  free  Cls  to  produce  a  measurable  ring.  The  extent  of 
release of Cls also correlates with activation. 
These  immunochemical  techniques  to  quantitate  C1  activation  directly  in 
serum do not require specialized reagents.  It is hoped that they will be useful 
in screening pathological sera and in monitoring the status of the complement 
system in patients. 
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